Korean Market
EXCH
JETEMA
★★★

JETEMA's Botulinum Toxin JTM201 Succeeds in China Phase 3 Trial: Non-inferiority to Botox Demonstrated, Green Light for China Market Entry

 
OWNR
JETEMA
★

JETEMA Executive Director Jeong Ha-jong Acquires 8,000 Shares via Stock Purchase Rights... Minor Increase, Limited Price Impact

 
PERI
JETEMA
★

Jetema: Q1 2026 Consolidated Revenue KRW 16B, Operating Loss Widens, Domestic Toxin Launch and Global Clinical Progress

 
OTHR
JETEMA
★

Jetema Corrects Stock Option Grant – Reduced Recipients and Shares Due to Resignations, Reflects Stock Dividend

 
OWNR
JETEMA
★

Shinhan Capital and Others File Large Shareholding Report for Simple Investment

 
OWNR
JETEMA
★

Large Shareholding Status Report – No Material Changes

 
EXCH
JETEMA
★

Jetema Changes Listing Tier from Premium to Venture

 
OWNR
JETEMA
★

Executives/Major Shareholders Securities Ownership Report Filed (No Data)

 
OWNR
JETEMA
★

Filing of Ownership Report for Executives and Major Shareholders (No Changes)

 
OWNR
JETEMA
★

Report on Ownership of Specific Securities by Executives and Major Shareholders (No Changes)